Baxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
Baxter Healthcare is voluntarily recalling MYXREDLIN insulin due to CGMP deviations. The recall covers specific lots distributed in the US, Puerto Rico, and Chile.
- Product
- MYXREDLIN — MYXREDLIN (INSULIN HUMAN)
- Category
- Drug
- Distribution
- Distributed nationwide